Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYNAMRO vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Adjunct to lipid-lowering medications and diet to reduce LDL-C, apo B, total cholesterol, and non-HDL-C in patients with homozygous familial hypercholesterolemia (Ho FH)
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Primarily metabolized by endonucleases and exonucleases. Not a substrate for CYP450 enzymes.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Greater than 90% bound to plasma proteins, predominantly albumin.
>95% bound to plasma proteins, primarily albumin.
Approximately 9.6 L/kg, indicating extensive tissue distribution (e.g., liver, kidney).
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Subcutaneous administration: approximately 90% bioavailability; not administered intravenously clinically.
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
No dose adjustment is required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Safety and efficacy in pediatric patients have not been established; not recommended for use in patients under 18 years of age.
Not recommended; safety and efficacy not established in pediatric patients.
No specific dose adjustments for elderly patients; clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
Risk of hepatotoxicity: Kynamro can cause elevations in serum transaminases and hepatic steatosis. Monitor liver function before and during treatment. Do not use in patients with moderate or severe hepatic impairment.
None
Hepatotoxicity: monitor ALT, AST, alkaline phosphatase, and total bilirubin before each dose; discontinue if clinically significant toxicity occurs.,Hepatic steatosis: may cause fatty liver; advise patients to report symptoms of liver injury.,Injection site reactions: common and may be severe.,Flu-like symptoms: common; may require symptomatic treatment.,Allergic reactions: including angioedema and urticaria.,Immune system effects: possible development of anti-drug antibodies and platelet count reductions.
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Moderate or severe hepatic impairment (Child-Pugh class B or C),Hypersensitivity to mipomersen or any component of the formulation,Active liver disease or unexplained persistent elevations of serum transaminases
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Avoid high-fat meals before and after injection. Take KYNAMRO at least 2 hours after any food and at least 1 hour before the next meal to minimize gastrointestinal side effects. No specific food-drug interactions known; however, the drug can increase hepatic fat, so a low-fat diet is generally recommended.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended during pregnancy unless clearly necessary.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
It is unknown if KYNAMRO is excreted in human milk. No M/P ratio available. A risk to the breastfed infant cannot be excluded; decision to discontinue breastfeeding or drug should consider importance of drug to mother.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No pharmacokinetic studies in pregnancy. No specific dose adjustment recommended; use only if potential benefit justifies potential risk. Standard dose: 200 mg subcutaneously once weekly.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
KYNAMRO (mipomersen) is an antisense oligonucleotide for homozygous familial hypercholesterolemia (Ho FH). It reduces LDL-C by inhibiting apo B-100 synthesis. Monitor for hepatotoxicity; require ALT, AST, alkaline phosphatase, and bilirubin before each dose. Injection site reactions are common; rotate sites. Consider a statin first-line in Ho FH if tolerated; mipomersen is adjunctive. Avoid in patients with significant liver disease or unexplained persistent transaminase elevations. Do not use in pregnancy due to risk of embryofetal toxicity.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
KYNAMRO is a weekly injection under the skin for homozygous familial hypercholesterolemia.,You must have blood tests to check your liver before each dose.,Common side effects include injection site redness, swelling, pain, or itching; flu-like symptoms; and nausea.,Do not take KYNAMRO if you are pregnant or planning to become pregnant; use effective contraception.,Take KYNAMRO on the same day each week, at least 2 hours after a meal and at least 1 hour before any food or other oral medications.,Store KYNAMRO in the refrigerator; do not freeze. Allow to warm to room temperature for 30 minutes before injecting.,Contact your doctor immediately if you experience yellowing of skin or eyes, dark urine, or severe abdominal pain.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYNAMRO vs ATROMID-S, answered by our medical review team.
KYNAMRO is a Antilipemic that works by Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYNAMRO and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYNAMRO is: Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYNAMRO and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYNAMRO is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended durin. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.